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Abstract
Background The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar inf-
liximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease (CD) in the 
main trial displayed a close to significant difference favouring originator infliximab, and more scientific data have therefore 
been requested.
Objective The aim was to assess treatment efficacy, safety, and immunogenicity in an explorative subgroup analysis in CD 
and ulcerative colitis (UC) in the NOR-SWITCH trials.
Patients and Methods The 52-week, randomised, non-inferiority, double-blind, multicentre, phase 4 NOR-SWITCH study 
was followed by a 26-week open extension trial where all patients received treatment with CT-P13. Treatment efficacy, safety, 
and immunogenicity in CD and UC were assessed throughout the 78-week study period.
Results The main and extension trials included 155 and 93 patients with CD and 93 and 80 patients with UC, respectively. 
Demographic and baseline characteristics were comparable in both treatment arms within patient groups. There were no dif-
ferences in the main and extension trials regarding changes in activity indices, C-reactive protein, faecal calprotectin, patient’s 
and physician’s global assessment of disease activity and patient-reported outcome measures in CD and UC. Moreover, com-
parable results were also demonstrated for trough serum levels, presence of anti-drug antibodies, and reported adverse events.
Conclusion Efficacy, safety, and immunogenicity of both the originator and biosimilar infliximab were comparable in CD 
and UC in the NOR-SWITCH main and extension trials. These explorative subgroup analyses confirm that there are no 
significant concerns related to switching from originator infliximab to CT-P13 in CD and UC.
Trial Registration ClinicalTrials.gov, number NCT02148640.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 9-020-00438 -7) contains 
supplementary material, which is available to authorized users.
 * Kristin K. Jørgensen 
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1 Introduction
Tumour necrosis factor alpha (TNFα) inhibitors and other 
biologic agents have had a substantial, positive impact on the 
treatment of several immune-mediated chronic inflammatory 
disorders, including inflammatory bowel disease (IBD) [1]. 
However, access to biologic treatment varies globally, with 
limited drug availability in many countries due to cost [2]. 
Biosimilars are less expensive reproductions of their origi-
nator counterparts and provide a potential opportunity to 
improve patient access.
The approval of the use of biosimilar infliximab CT-P13 
 (Remsima®,  Inflectra®, Celltrion, Inchon, South Korea) in 
IBD is extrapolated from two pivotal studies conducted in 
patients with rheumatic diseases (PLANETAS and PLAN-
ETRA) [3, 4]. Although there are similarities between IBD 
and rheumatic diseases, monoclonal antibodies such as inf-
liximab may interact in subtly different ways in different 
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Key Points 
The randomised, controlled, double-blind NOR-
SWITCH study demonstrated that switching from origi-
nator infliximab to CT-P13 is efficacious and safe across 
six indications. However, a subgroup analysis of Crohn’s 
disease displayed a close to significant difference in 
terms of efficacy favouring originator infliximab.
This explorative subgroup analysis of Crohn’s disease 
and ulcerative colitis in the NOR-SWITCH main and 
extension trials displays comparable results regarding 
clinical, biochemical, immunogenicity, and patient-
reported outcome measures between originator inflixi-
mab and CT-P13.
Long-term treatment with CT-P13 is efficacious and safe 
in inflammatory bowel disease.
non-inferiority, comparative, phase 4 study, in a hospital set-
ting. Patient recruitment, inclusion, and exclusion criteria 
have previously been described in detail [19]. A nationwide 
project group including representatives from all relevant spe-
cialties together with patient representatives planned and 
conducted the study. Adult patients with a diagnosis of CD 
and UC on stable treatment with IFX for at least 6 months 
were eligible for participation. The patients who completed 
the main study period (week 0 to week 52) were recruited 
to the open, 26-week follow-up extension trial (week 52 to 
week 78). All patients received verbal and written infor-
mation about the main and extension study and signed an 
informed consent. The study was conducted in compliance 
with the Declaration of Helsinki and the International Con-
ference on Harmonization Guidelines for Good Clinical 
Practice. The study protocol and consent documents were 
approved by an independent ethics committee (Regional 
Committees for Medical and Health Research Ethics South 
East; reference number 2014/848), by appropriate insti-
tutional review boards, and by the Norwegian Medicines 
Agency (reference number 14/07192-11).
2.2  Randomisation and Masking
In the main study, eligible patients were randomised 1:1 to 
either continued treatment with IFX or a switch to CT-P13 
treatment. The type of IFX treatment was blinded, and the 
dose and infusion intervals of patients’ treatment regimens 
were kept unchanged from those before randomisation. 
After completion of the main study, the 26-week exten-
sion study recruited consenting patients who were all given 
open-label CT-P13 treatment with an unchanged regimen 
in terms of dose and infusion intervals. The patients treated 
with CT-P13 in the main trial continued this treatment in 
the extension phase (CT-P13 maintenance group), whereas 
patients treated with IFX switched to CT-P13 in the exten-
sion phase (IFX/CT-P13 switch group). Consequently, the 
CT-P13 maintenance group received CTP13 for 18 months 
and the IFX/CT-P13 switch group received CT-P13 for 
6 months (after 12 months with IFX in the main study) 
(Fig. 1) [24]. The blinded treatment allocation in the main 
study was not revealed until after completion of the exten-
sion study period.
2.3  Study Assessments
Data were collected at every infusion visit, including clinical 
assessments by a trained study nurse and/or physician using 
an electronic case report form  (Viedoc®). Blood samples 
for protocol-specified laboratory tests were obtained before 
infusions, including measurements of drug concentrations 
and anti-drug antibodies (ADAbs), and for storage in a 
biobank. IFX and CT-P13 trough serum levels and ADAbs 
diseases; in IBD, blocking of both soluble and membrane 
bound TNFα is of importance [5]. Thus, it has been sug-
gested that the clinically relevant mechanisms of action of 
infliximab might differ in different diseases [6] and there 
were some concerns in the gastroenterology community 
when biosimilar infliximab became available for use in clini-
cal practice [7, 8].
So far, no real-life clinical studies have shown any unex-
pected effects when starting patients on CT-P13 or switch-
ing from infliximab originator (IFX)  (Remicade®, Janssen, 
Beerse, Belgium) to CT-P13 [9–18]. The NOR-SWITCH 
study showed that switching from IFX to CT-P13 was not 
inferior to continued treatment with IFX regarding efficacy, 
safety, and immunogenicity across six indications [19]. 
However, sub-analyses of the primary endpoint in Crohn’s 
disease (CD) demonstrated a confidence interval (CI) for 
CT-P13 just within the prespecified non-inferiority mar-
gin (risk difference −14.3%, 95% CI −29.3 to 0.7) [19]. 
This finding might indicate a less favourable outcome after 
switching from reference product to biosimilars in CD, and 
more scientific data have been requested [20–23].
Here we present the complete results regarding efficacy, 
safety and immunogenicity from the subgroup analyses of 
CD and ulcerative colitis (UC) patients from both the main 
and extension part of the NOR-SWITCH study [19, 24].
2  Methods
2.1  Study Design and Participants
The NOR-SWITCH main study was designed as a 52-week, 
randomised, double-blind, parallel-group, multicentre, 
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were analyzed using in-house assays automated on the 
 AutoDELFIA® (PerkinElmer, Waltham, MA) immunoassay 
platform [19]. ADAbs were not analyzed in samples with 
IFX/CT-P13 levels above 5 mg/L, since high drug concen-
trations cause interference in our assays. The patients were 
asked to deliver a faecal sample for calprotectin measure-
ments after each visit (CalproLab, Calpro AS, Oslo, Norway; 
Buhlmann Laboratories AG, Basel, Switzerland). The num-
ber of study visits differed according to treatment regimen. 
Full details about the collected variables can be found in the 
main study report [19].
2.4  Outcomes
The primary endpoint was disease worsening during the 
52-week main study and the subsequent 26-week extension 
study [19, 24]. Disease worsening was defined by worsening 
in Harvey-Bradshaw Index (HBI) for CD (a change from 
baseline of 4 points or more and a total score of 7 points or 
greater) and partial Mayo Score (PMS) for UC (a change 
from baseline of more than 3 points and a total score of 5 
or greater) or a consensus on disease worsening between 
investigator and patient leading to major change in treat-
ment. Secondary endpoints included clinical remission sta-
tus (HBI ≤ 4 points, PMS ≤ 2 points), levels of C-reactive 
protein (CRP) and faecal calprotectin, changes in disease 
variables and investigator and patient global assessments 
(follow-up minus baseline), patient-reported outcome meas-
ures (PROMs), drug concentrations (trough measurements), 
and ADAb assessments. Measures of safety included clinical 
and laboratory adverse events (AEs). The coding of AEs was 
Fig. 1  Patient disposition in IBD in the NOR-SWITCH main and 
extension study. CD Crohn’s disease, IBD inflammatory bowel dis-
ease, IFX infliximab, PPS per-protocol set, UC ulcerative colitis. 
1 Four CD patients withdrew consent, two CD and one UC patients 
had major change in immunosuppressive treatment, two CD patients 
were unblinded during the study, two CD patients developed adverse 
events, and one CD patient was excluded for other reasons. 2 Seven 
CD and four UC patients withdrew consent, two CD and five UC 
patients had major change in immunosuppressive treatment, two 
CD patients were unblinded during the study, one CD and two UC 
patients developed adverse events, three CD patients and one UC 
patient were excluded for other reasons
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performed according to the Medical Dictionary for Regula-
tory Activities (MedDRA, v.13.0).
2.5  Statistical Analyses
The statistical analyses have previously been described in 
detail [19]. A power calculation to demonstrate non-inferi-
ority of 15% was performed for the entire study population 
including the six subgroups. The per-protocol set (PPS) con-
sisted of subjects without major protocol deviations through-
out the main and extension study, while the full analysis set 
(FAS) comprised all subjects entering the main and exten-
sion study, respectively. We analysed the primary outcome 
and secondary dichotomous endpoints using logistic regres-
sion, with treatment as a fixed effect, adjusted for diagno-
sis and the treatment duration of IFX at baseline (week 0), 
providing estimates (by the delta method) of adjusted risk 
difference and adjusted relative risk for the treatment dif-
ference. Continuous outcomes were analyzed using linear 
mixed effect models, with treating time as a categorical vari-
able and including a time by treatment group interaction. 
Missing data for remission and disease worsening in the FAS 
were imputed with last observation carried forward.
2.6  Role of the Funding Source
The funder of the study (the Norwegian Ministry of Health 
and Care Services) had no role in study design, data collec-
tion, data analysis, data interpretation, writing of this article, 
or decision to submit. All authors reviewed and approved the 
final manuscript. The corresponding author (KKJ) together 
with the statistician (JS) had full access to all the data in the 




Between October 2014 and July 2016, 248 IBD patients (155 
CD, 93 UC) were enrolled and randomised into the NOR-
SWITCH main trial at 19 gastroenterology study centres. 
Based on randomisation, 123 patients switched treatment 
from IFX to CT-P13 and 125 patients continued treatment 
with IFX (Fig. 1). Of the 230 patients who completed the 
52-week main trial, 207 (90%) (127 CD, 80 UC) continued 
into the 26-week open extension study (Fig. 1). Two of the 
19 study centres did not recruit patients to the extension 
phase.
3.1.1  Main Study
In the FAS, the mean age at inclusion was 38.8 years (SD 
13.8) in CD patients and 45.2 years (SD 14.4) in UC patients. 
The mean disease duration was 13.6 (SD 8.8) and 11.3 years 
(SD 8.3) and the mean duration of ongoing IFX treatment 
at randomisation was 5.5 (SD 3.4) and 4.3 years (SD 2.3) in 
CD and UC patients, respectively. The demographics and 
baseline characteristics of the randomised patients with IBD 
are listed in Table 1. The majority of patients were biologic 
treatment–naïve prior to initiating ongoing IFX treatment, 
and almost half of the patients used concomitant immuno-
suppressive treatment (Table 1). Both the general and the 
disease-specific measures suggested low disease activity at 
baseline, with no differences between groups (Table 1).
3.1.2  Extension Study
In the FAS, there were 65 (61%) and 62 (62%) CD patients 
and 42 (39%) and 38 (38%) UC patients in the CT-P13 
maintenance and IFX/CT-P13 switch groups, respectively 
(Fig. 1). The demographics and baseline characteristics 
(week 52) were comparable to the cohort of the main study 
(see the Electronic Supplementary Material, Table S1). As 
in the main study, disease activity at baseline (week 52) in 
both CD and UC patients was generally low with no differ-
ences between groups (Table S1).
3.2  Primary Endpoint
3.2.1  Main Study
In CD, disease worsening occurred in 23 out of 63 patients 
(36.5%) in the CT-P13 group and in 14 out of 66 patients 
(21.2%) in the IFX group (PPS). The 95% CI of the adjusted 
risk difference of −14.3% was −29.3 to 0.7 [19]. A total 
of 46 disease worsening events were recorded (in some 
patients, more than one event). Of these, 18 were associated 
with a change in study drug dosage, and one with study 
drug discontinuation. In UC, disease worsening occurred in 
five out of 42 patients (11.9%) and three out of 33 patients 
(9.1%) in the CT-P13 and IFX group, respectively (adjusted 
risk difference −2.6%, 95% CI −15.2 to 10.0) [19]. Of these, 
two were associated with a change in study drug dosage; no 
study drug discontinuations occurred.
3.2.2  Extension Study
In CD, disease worsening occurred in 13 out of 63 patients 
(20.6%) in the CT-P13 maintenance group and in eight out 
of 61 patients (13.1%) in the IFX/CT-P13 switch group 
(PPS). The 95% CI of the adjusted risk difference of 7.9% 
was −5.2 to 21 [24]. In 11 patients, disease worsening was 
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Table 1  Demographics and baseline characteristics in main study (week 0) in CD and UC, full analysis set
Data are n (%), mean (SD), or median (25–75 percentiles). 95% CI = 95% confidence interval of the adjusted treatment difference
CD Crohn’s disease, EQ-5D EuroQol questionnaire time trade-off (UK weighted), GI gastrointestinal, IFX infliximab, UC ulcerative colitis
*Ref. [19]
† Some patients had undergone more than one procedure
‡ Immunosuppressive therapy includes azathioprine, 6-mercaptopurine, and methotrexate










Age (years) 39.5 (14.2) 38.0 (13.4) 44.4 (14.8) 45.8 (14.1)
Female 30 (39%) 33 (42%) 14 (30%) 18 (38%)
Disease duration (years) 14.3 (8.5) 12.8 (9.0) 11.5 (7.5) 11.2 (9.2)
Duration of ongoing IFX treatment (years) 5.2 (3.3) 5.7 (3.5) 4.3 (2.5) 4.2 (2.1)
CD distribution
Ileum (L1) 13 (17%) 13 (17%) – –
Colonic (l2) 23 (30%) 25 (32%) – –
Ileocolonic (L3) 38 (49%) 39 (50%) – –
Upper GI tract (L4) 6 (9%) 7 (10%) – –
CD type
Non-stricturing, non-penetrating (B1) 43 (56%) 43 (55%) – –
Stricturing (B2) 16 (21%) 17 (22%) – –
Penetrating (B3) 18 (23%) 18 (23%) – –
Perianal disease 30 (39%) 20 (26%) – –
UC distribution
Ulcerative proctitis (E1) – – 0 1 (2%)
Proctosigmoiditis – – 6 (13%) 6 (13%)
Left sided (E2) – – 6 (13%) 11 (23%)
Pancolitis (E3) – – 34 (74%) 29 (62%)
Surgery† 36 (47%) 32 (41%) 0 0
Ileocoecal resection 15 (42%) 16 (50%) – –
Perianal disease 12 (33%) 10 (31%)
Internal fistula/abscess 8 (22%) 8 (25%) – –
Small bowel resection/stricturoplastic 11 (14%) 10 (13%) – –
Colonic resection 5 (14%) 5 (16%) – –
Concomitant therapies
Immunosuppressive  therapy‡ * 36 (47%) 30 (38%) 20 (43%) 19 (40%)
Prednisolone* 0 2 (3%) 1 (2%) 3 (6%)
Pre-infusion steroids IV 6 (8%) 8 (10%) 0 1 (2%)
Previous therapies
Biologic treatment naive* 60 (78%) 61 (78%) 43 (93%) 45 (96%)
One previous* 17 (22%) 17 (22%) 2 (4%) 2 (4%)
Two previous* 0 0 1 (2%) 0
Current smokers 17 (22%) 13 (17%) 4 (9%) 3 (6%)
Disease characteristics*
C-reactive protein (mg/L) 1.3 (1.0–5.0) 2.8 (1.0–5.0) 1.1 (1.0–5.0) 1.4 (1.0–5.0)
Faecal calprotectin (mg/kg) 65 (27–210) 70 (32–191) 40 (19–208) 44 (19–111)
Harvey-Bradshaw Index 2 (0–4) 2 (1–4) – –
Partial Mayo Score – – 0 (0–1) 0 (0–1)
Patient’s global assessment of disease activity (0–10) 1.8 (2.0) 1.8 (1.7) 1.4 (1.9) 1.0 (1.4)
Physician’s global assessment of disease activity (0–10) 1.2 (1.2) 1.4 (1.3) 1.0 (1.7) 0.6 (1.1)
EQ-5D index score 0.8 (0.2) 0.8 (0.2) 0.9 (0.2) 0.9 (0.1)
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recorded for the first time during the study period; six in 
the maintenance group and five in the IFX/CT-P13 switch 
group. A total of 28 disease worsening events were recorded 
(in some patients, more than one event). Seven events were 
associated with a change in study drug dosage. In UC, dis-
ease worsening occurred in six out of 39 patients (15.4%) in 
the CT-P13 maintenance group and in one out of 35 patients 
(2.9%) in the IFX/CT-P13 switch group (adjusted risk dif-
ference 12.4%, 95% CI −0.1 to 25) [24]. In six patients, 
disease worsening was recorded for the first time during the 
study period; five in the maintenance group and one in the 
IFX/CT-P13 switch group. A total of nine disease worsen-
ing events were recorded (in some patients, more than one 
event); four of these were associated with a change in study 
drug dosage. No study drug discontinuations were associ-
ated with disease worsening in the CD and UC patients in 
the study groups.
No predictive factors for disease worsening in CD and UC 
in the main and extension part of the study were identified 
(Table S3a and S3b).
3.3  Secondary Endpoints
At the end of the main study (week 52), clinical remission 
was present in CD in 41 out of 63 patients (65%) and 46 
out of 66 patients (70%) in the CT-P13 and IFX groups, 
respectively (adjusted risk difference 5.6%, 95% CI −11 to 
22.2) (PPS) [19]. In UC, 39 out of 42 patients (93%) and 29 
out of 33 patients (88%) were in clinical remission in the 
CT-P13 and IFX groups, respectively (adjusted rate differ-
ence −5.9%, 95% CI −21.7 to 9.9) [19]. At the end of the 
extension study (week 78), clinical remission was present in 
CD in 41 out of 63 patients (65%) and 46 out of 61 patients 
(75%) in the CT-P13 maintenance and IFX/CT-P13 switch 
groups, respectively (adjusted risk difference −11.3%, 95% 
CI −27.2 to 4.5) [24]. In UC, 32 out of 39 patients (82%) 
and 30 out of 35 patients (86%) were in clinical remission 
in the CT-P13 maintenance group and IFX/CT-P13 switch 
group, respectively (adjusted risk difference −3.3%, 95% CI 
−20 to 13.4). [24].
Of the patients entering the extension study, 90 CD and 
75 UC patients were in clinical remission (last visit in main 
study), compared to 88 and 68 patients, respectively, at the 
last visit in the extension study.
Disease state at baseline and changes in the disease varia-
bles from baseline (week 0) to the end of the extension study 
(week 78) demonstrated no significant differences between 
the two groups in CD and UC (PPS) (see Tables 2a and 2b, 
and Tables S2a and S2b in the Electronic Supplementary 
Material). Likewise, the changes in PROMs were generally 
similar in the two groups, in both CD and UC (Tables 2a and 
2b, Tables S2a and S2b).
Figures 2 and 3 present the disease-specific composite 
measures, CRP, faecal calprotectin, serum infliximab, and 
patient’s and physician’s global assessment of disease wors-
ening in CD (Fig. 2) and UC (Fig. 3) throughout the main 
and extension study (week 0–78). No significant differences 
for any of these parameters were found between treatment 
arms in the two groups.
Throughout the main study, 13 CD patients discontinued 
the study: six in the CT-P13 group and seven in the IFX 
group (FAS). In UC, six patients discontinued the study: one 
in the CT-P13 group and five in the IFX group (FAS). Two 
CD patients (one due to low serum levels, one due to “other 
reasons”) and three UC patients (two due to AEs, one due to 
low serum levels) discontinued the study drug.
Throughout the extension study, nine patients discontin-
ued the study: three CD patients and six UC patients (FAS) 
(Fig. 1). One patient with CD discontinued the study drug 
(due to “other reasons”).
4  Adverse Events
Similar numbers of patients had at least one treatment emer-
gent AE in the two treatment groups in CD and UC in the 
main and extension study (FAS) (Table 3). Likewise, the 
number of patients with a treatment-emergent serious AE 
did not differ between the two groups in the two diseases 
(Table 3). The most frequent treatment-emergent AEs were 
related to infections in both diseases (Table 3). No deaths 
occurred.
4.1  Anti‑drug Antibodies
The incidence of ADAbs detected at any time during the 
main study (excluding patients with detectable ADAbs at 
baseline) in CD was four out of 77 (5%) in the CT-P13 group 
and three out of 78 (4%) in the IFX group (FAS). In UC, 
eight out of 46 patients (17%) in the CT-P13 group and five 
out of 47 patients (11%) in the IFX group developed new 
ADAbs. In the extension study, none of the CD patients in 
the CT-P13 maintenance group and one out of 62 (1.6%) in 
the IFX/CT-P13 switch group developed ADAbs. In UC, one 
out of 42 (2.4%) in the CT-P13 maintenance group and one 
out of 38 (2.6%) in the IFX/CT-P13 switch group developed 
ADAbs. Trough drug concentrations were similar in the two 
groups for both diseases (Figs. 2 and 3).
5  Discussion
The NOR-SWITCH study is the first randomised study 
demonstrating that switching from IFX to CT-P13 is safe 
[19], but due to the large difference in efficacy favouring 
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IFX in CD patients this conclusion has been questioned for 
this subgroup [20–22]. In the exploratory sub-analyses of 
IBD patients involving both the main and extension part 
of the NOR-SWITCH trial, we demonstrate comparable 
results for IFX and CT-P13 across treatment arms in terms 
of efficacy, safety, and immunogenicity. Hence, the suspicion 
of inferiority of CT-P13 compared to IFX in CD is refuted.
Disease worsening based on HBI and PMS as the primary 
endpoint has clear weaknesses since these activity indices 
mainly consist of subjective assessments of symptoms by 
the patient. However, the secondary endpoints of the study, 
Table 2a  Secondary efficacy endpoints in the main study (week 0–52) in Crohn’s disease, per-protocol set
Data are mean (SD) at baseline and mean (SD) change from baseline (follow-up minus baseline). Difference is adjusted treatment difference of 
change from baseline with 95% CI
CI confidence interval, EQ-5D EuroQol questionnaire time trade-off UK weighted, IBDQ Inflammatory Bowel Disease Questionnaire, WPAI 
Work Productivity and Impairment Questionnaire
*Ref. [19]










Harvey-Bradshaw Index* 2.62 (2.39) 2.58 (2.4) 3.13 (3.69) 2.83 (3.14) 0.28 (−0.52 to 1.08)
Physician’s global assessment 
of disease activity
1.3 (1.25) 1.27 (1.26) 1.85 (1.79) 1.52 (1.98) 0.29 (−0.26 to 0.84)
Patient’s global assessment of 
disease activity
1.79 (2.02) 1.66 (1.58) 2.58 (2.39) 1.92 (1.89) 0.60 (−0.05 to 1.25)
C-reactive protein (mg/L), 
log10
0.50 (0.3) 0.52 (0.32) 0.58 (0.39) 0.56 (0.34) 0.04 (−0.05 to 0.13)
Faecal calprotectin (mg/kg), 
log10
1.97 (0.7) 1.87 (0.53) 2.17 (0.62) 1.98 (0.6) 0.05 (−0.13 to 0.24)
Patient-reported outcome measures
SF-36 physical functioning 91.76 (13.81) 92.63 (9.21) 91.69 (15.88) 90.47 (15.13) 1.86 (−1.42 to 5.15)
SF-36 role limitation physical 69.76 (38.98) 70.56 (36.64) 64.83 (43.83) 67.21 (41.22) −2.72 (−14.18 to 8.74)
SF-36 pain 77.78 (22.68) 78.03 (20.34) 76.44 (21.86) 75.78 (26.37) 0.53 (−5.86 to 6.93)
SF-36 general health 61.83 (22.69) 61.21 (23.27) 57.46 (24.08) 61.23 (25.7) −4.69 (−9.78 to 0.41)
SF-36 emotional well-being 81.14 (15.2) 73.88 (19.45) 77.63 (18.15) 71.41 (21.1) −0.74 (−5.34 to 3.86)
SF-36 role limitation emo-
tional
85.19 (30.4) 73.23 (36.15) 71.19 (40.8) 73.22 (36.93) −10.83 (−21.82 to 0.15)
SF-36 social functioning 83.73 (21.02) 83.33 (21.74) 81.57 (24.93) 81.97 (25.87) −2.38 (−8.66 to 3.91)
SF-36 energy fatigue 51.83 (20.68) 54.72 (21.48) 51.95 (26.59) 49.92 (27.82) 4.47 (−1.51 to 10.45)
SF-36 physical component 
summary score
48.46 (9.67) 50.55 (6.62) 48.8 (8.36) 49.63 (9.02) 0.63 (−1.44 to 2.7)
SF-36 mental component sum-
mary score
49.28 (9.21) 45.57 (12.79) 46.22 (12.89) 44.68 (13.41) −2.17 (−5.22 to 0.89)
EQ-5D index 0.84 (0.15) 0.83 (0.18) 0.82 (0.18) 0.80 (0.24) 0 (−0.06 to 0.06)
WPAI percentage work missed 
due to specified problem 
(absenteeism)
0.08 (0.24) 0.04 (0.11) 0.09 (0.21) 0.04 (0.13) 0.03 (−0.06 to 0.12)
WPAI percentage impairment 
while working due to speci-
fied problem (presenteeism)
0.12 (0.18) 0.16 (0.21) 0.21 (0.25) 0.16 (0.23) 0.10 (0 to 0.19)
WPAI percentage overall work 
impairment due to specified 
problem
0.15 (0.22) 0.18 (0.23) 0.27 (0.28) 0.16 (0.22) 0.14 (0.02 to 0.25)
WPAI percentage activity 
impairment due to specified 
problem
0.22 (0.26) 0.21 (0.25) 0.26 (0.28) 0.22 (0.27) 0.04 (−0.03 to 0.12)
IBDQ total score 184.20 (26.30) 187.50 (23.10) 184 (31.90) 182.10 (31.50) 3.50 (−2.75 to 9.70)
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i.e. pharmacokinetics and the inflammatory markers (CRP 
and faecal calprotectin), provide more objective information 
that clearly supports biosimilarity. Endoscopic assessment is 
important to evaluate disease activity in IBD patients. Unfor-
tunately, this was not included in our study due to practical 
reasons and possible negative impact on patient inclusion. 
However, previous studies have demonstrated a clear cor-
relation between endoscopic findings and faecal calprotec-
tin [25]. Throughout the study fewer UC than CD patients 
experienced disease worsening. Due to the low number of 
Table 2b  Secondary efficacy endpoints in the main study (week 0–52) in ulcerative colitis, per-protocol set
Data are mean (SD) at baseline and mean (SD) change from baseline (follow-up minus baseline). Difference is adjusted treatment difference of 
change from baseline with 95% CI
CI confidence interval, EQ-5D EuroQol questionnaire time trade-off UK weighted, IBDQ Inflammatory Bowel Disease Questionnaire, WPAI 
Work Productivity and Impairment Questionnaire
*Ref. [19]










Partial Mayo Score* 0.62 (1.31) 0.61 (1.32) 0.45 (1.06) 0.66 (1.12) −0.23 (−0.71 to 0.25)
Physician’s global assessment 
of disease activity
0.88 (1.56) 0.70 (1.19) 0.93 (1.4) 0.81 (1.45) 0.08 (−0.53 to 0.70)
Patient’s global assessment of 
disease activity
1.31 (1.75) 0.94 (1.60) 1.43 (1.99) 1.34 (1.79) −0.05 (−0.86 to 0.77)
C-reactive protein (mg/L), 
log10
0.49 (0.32) 0.52 (0.35) 0.53 (0.27) 0.48 (0.25) 0.04 (−0.08 to 0.170)
Faecal calprotectin (mg/kg), 
log10
1.77 (0.62) 1.82 (0.66) 1.76 (0.63) 1.83 (0.77) −0.09 (−0.38 to 0.20)
Patient-reported outcome 
measures
SF-36 physical functioning 92.32 (14.41) 89.24 (17.07) 92.18 (15.03) 91.91 (13.17) −1.03 (−5.01 to 2.96)
SF-36 role limitation physical 78.12 (35.44) 70.31 (38.85) 80.92 (32.59) 84.17 (27.45) −6.17 (−20.05 to 7.71)
SF-36 pain 86.04 (21.77) 77.73 (19.99) 81.09 (22.6) 84.08 (17.13) −5.57 (−13.49 to 2.34)
SF-36 general health 70.61 (22.06) 69.53 (21.15) 67.88 (25.11) 69.5 (24.99) 0.43 (−6.09 to 6.94)
SF-36 emotional well-being 77.85 (15.13) 82 (12.57) 79.07 (14.87) 82 (13.52) 0.19 (−5.12 to 5.49)
SF-36 role limitation emo-
tional
76.42 (35.94) 82.29 (33.85) 78.07 (33.13) 90 (26.48) −6.91 (−19.01 to 5.2)
SF-36 social functioning 87.20 (18.22) 87.50 (19.05) 87.82 (18.91) 95.42 (11.6) −6.86 (−13.48 to −0.24)
SF-36 energy fatigue 56.34 (22.05) 56.56 (19.36) 58.59 (25) 57.17 (23.73) 4.68 (−3.49 to 12.84)
SF-36 physical component 
summary score
53.10 (8.21) 49.18 (8.99) 52.08 (8.44) 51.19 (7.4) −1.30 (−4.03 to 1.43)
SF-36 mental component sum-
mary score
46.63 (10.15) 50.10 (8.97) 48.29 (9.95) 51.51 (6.26) −1.00 (−4.5 to 2.5)
EQ-5D index 0.86 (0.18) 0.87 (0.12) 0.85 (0.2) 0.88 (0.12) −0.01 (−0.08 to 0.06)
WPAI percentage work missed 
due to specified problem 
(absenteeism)
0.08 (0.25) 0.03 (0.07) 0.08 (0.2) 0.04 (0.13) 0.01 (−0.11 to 0.13)
WPAI percentage impairment 
while working due to speci-
fied problem (presenteeism)
0.12 (0.24) 0.09 (0.15) 0.17 (0.24) 0.12 (0.16) 0.02 (−0.09 to 0.13)
WPAI percentage overall work 
impairment due to specified 
problem
0.17 (0.31) 0.13 (0.19) 0.21 (0.3) 0.13 (0.19) 0.03 (−0.11 to 0.18)
WPAI percentage activity 
impairment due to specified 
problem
0.18 (0.28) 0.15 (0.24) 0.21 (0.28) 0.11 (0.18) 0.05 (−0.04 to 0.13)
IBDQ total score 191 (22.47) 193.54 (21.05) 191.83 (23.32) 198.08 (18.29) −3.43 (−10.49 to 3.62)
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UC patients reaching the primary endpoint, no conclusions 
can be drawn regarding the risk difference between treatment 
arms in the extension part of the study.
There were no new safety signals during the main study 
and the extension study period, and AEs were evenly dis-
tributed between study arms in both CD and UC patients. As 
expected, the most frequent AEs reported were infections. 
Immunogenicity with the formation of ADAbs is of great 
importance in relation to both AEs and loss of response to 
treatment. Drug levels and ADAbs were therefore measured 
at every visit throughout the entire study period, and no dif-
ferences were demonstrated between the two treatment arms 
in UC and CD. Thus, the results support that there is no 
increased risk of immunogenicity after switching to CT-P13 
in IBD patients.
The NOR-SWITCH trial has both strengths and weak-
nesses. The randomised multicentre design and the involve-
ment of patient representatives in the planning and conduct 
Fig. 2  Secondary efficacy endpoints in Crohn’s disease from randomisation in main study (baseline/week 0) to study end (week 78), per-protocol 
set. IFX infliximab
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of the study are obvious strengths. Moreover, the study was 
financed by the Norwegian Government and monitored 
within the healthcare system, completely independent of 
pharmaceutical companies. One limitation of the subgroup 
analyses of IBD is that the power calculation to demonstrate 
non-inferiority applies for the entire study population and 
not each diagnostic group. However, the majority of patients 
included in the study had IBD (51%), with CD as the most 
common diagnosis (n = 155; 32%). In our opinion, these 
facts together with the controversy that was raised around 
the potential non-inferiority of CT-P13 when compared to 
IFX for CD justifies a separate and more comprehensive 
presentation of the IBD subgroup analyses. We consider 
the results to contribute to our knowledge in the field of 
biosimilars where randomised data are sparse, especially in 
IBD. Furthermore, valuable information is added to the dis-
cussion regarding the possible loss of response in CD under 
CT-P13 treatment.
Fig. 3  Secondary efficacy endpoints in ulcerative colitis from randomisation in main study (baseline/week 0) to study end (week 78), per-proto-
col set. IFX infliximab
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To our knowledge, the only randomised controlled IFX 
switch trial besides the NOR-SWITCH study is described 
in a paper by Ye et al. [26]. They included anti-TNF–naïve 
CD patients with moderate to severe disease, who received 
either treatment with CT-P13 or IFX. At week 30, half of 
the patients in each group switched to IFX and CT-P13, 
respectively, and comparable results regarding efficacy and 
safety were seen in all four groups at week 54 [26]. Similar 
to our study, which lacked the power to separately evaluate 
the non-inferiority of switching in the IBD subpopulation, 
this study was not powered to assess the non-inferiority of 
switching beyond week 30. The patient cohort, encompass-
ing CD patients with short treatment duration, is not directly 
comparable to our study cohort with stable CD patients with 
long-term treatment of IFX before randomisation.
The nocebo effect is an important issue when switch-
ing from originator to biosimilar medicines, because of a 
possible impact on treatment success [27, 28]. Studies in 
IBD have demonstrated a nocebo effect after switching 
from originator to biosimilar infliximab; Boone et al. found 
an overall nocebo response of 13% 6 months after switch 
in a pragmatic switch study involving mainly CD and UC 
patients [28]. No significant changes in objective effective-
ness and safety were proven. On the contrary, Razanskaite 
et al. demonstrated no deterioration in clinical and patient-
reported outcomes after an open prospective switch in 143 
IBD patients [29]. Importantly, in the NOR-SWITCH main 
study, we avoided the nocebo effect on a group level due 
to the double-blind design. However, when looking at the 
overall patient’s and physician’s global assessment of dis-
ease activity throughout this study, an upward drift can be 
observed in the patient’s assessment in both study arms, 
indicating a nocebo effect [30]. Our IBD substudy does not 
demonstrate a similar drift as previously described, not in 
Table 3  Treatment-emergent adverse events in Crohn’s disease and ulcerative colitis in the main and extension study, safety population
Data are number of events/number of patients (%)
IFX infliximab, SUSAR suspected unexpected serious adverse reaction
† Minor infections: cold, otitis, sinusitis, flu, urinary tract infections, gastroenteritis, cholecystitis
Main study (week 0–52) Extension study (week 52–78)






















SUSAR 0 0 0 0 0 0 0 0
Serious adverse events 9/8 (10%) 9/8 (10%) 3/3 (7%) 4/4 (9%) 7/6 (9%) 4/3 (5%) 0 2/2 (5%)




42/24 (37%) 28/18 (29%) 17/12 (29%) 20/14 (37%)
Adverse events leading to 
study drug discontinu-
ation
2 (2.6%) 1 (1.3%) 0 (0%) 2 (4.3%) 0 (0%) 1 (1.6%) 0 (0%) 0 (0%)
Most frequent treatment-emergent adverse events
Minor  infections† 21/18 (23%) 16/15 (19%) 8/8 (17%) 4/4 (9%) 8/8 (12%) 3/3 (5%) 7/6 (14%) 8/8 (21%)
Iron deficiency 3/3 (4%) 2/2 (3%) – – 3/2 (3%) 2/1 (2%) – –
Infusion-related reaction – – 1/1 (2%) 2/2 (4%) 3/3 (5%) – – –
Kidney stones – – – – 1/1 (2%) 2/1 (2%) – –
Nausea – – – – 1/1 (2%) 1/1 (2%) – –
Rash 5/5 (6%) – 3/3 (7%) 4/4 (9%) 1/1 (2%) 3/3 (5%) – –
Back pain – – – – – – 1/1 (2%) 1/1 (3%)
Headache 1/1 (1%) 5/5 (6%) 1/1 (2%) 2/1 (2%) – – – –
Depression 1/1 (1%) 3/3 (4%) – – – – – –
Joint pain 1/1 (1%) 3/3 (4%) – – – – – –
Elevated liver enzymes – – 4/3 (7%) 1/1 (1%) – – – –
Cataract – – 1/1 (2%) – – – – –
Amaurosis fugax – – – – – – 1/1 (2%) –
Anaemia – – – – – – – 1/1 (3%)
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CD, nor in UC. In the extension part of our study, one might 
expect a nocebo effect due to the open study design. How-
ever, both our patients and the healthcare workers remained 
blinded to what treatment the patients had been given dur-
ing the main study period. Perhaps for these reasons, we do 
not see a clearly delineated nocebo effect in the CD and UC 
patients in the extension part of the trial.
6  Conclusions
In summary, we conclude that there were no significant 
differences regarding efficacy, safety and immunogenicity 
between patients treated with IFX or CTP-13 within the CD 
and UC patient groups when evaluating the NOR-SWITCH 
trials together. Therefore, the subgroup analyses support that 
a switch from originator to biosimilar infliximab can be rec-
ommended in IBD patients.
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